Subpial delivery technology has the potential to offer precise, efficient, and safer delivery of gene therapies for neurological diseases with spinal cord involvement Studies in large animal
An international team of researchers, led by scientists at University of California San Diego School of Medicine, report that a gene therapy that inhibits
Gene therapy that inhibits targeted nerve cell signals effectively improves symptoms of neuropathic pain without negative side effects in mouse models of spinal cord injury or peripheral nerve damage.
Gene therapy reveals promise in treating neuropathy from spinal cord injuries miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
Established Exclusive Worldwide Collaboration and License Agreement with Roche and Genentech for the Development and Commercialization of RG6501 (OpRegen®) in Transaction Worth up to $670 MillionRetinal Tissue Restoration and Visual Improvements Reported in Four Patients Treated with RG6501 (OpRegen) for Dry Age-Rel.